metformin has been researched along with Diabetic Glomerulosclerosis in 179 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, if used in excessive doses for patients with kidney disease, it will be contraindicated with side effects such as lactic acidosis." | 9.22 | Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease. ( Rahman, F; Tuba, S, 2022) |
| "The aim of his study was to compare the efficacy of pioglitazone with metformin on the reduction of albuminuria in type 2 diabetic patients with hypertension and microalbuminuria treated with renin-angiotensin system inhibitors (RAS-Is)." | 9.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| "Troglitazone ameliorated microalbuminuria in diabetic nephropathy." | 9.08 | Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. ( Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y, 1998) |
| "Metformin (MF) accumulation during acute kidney injury is associated with high anion gap lactic acidosis type B (MF-associated lactic acidosis, MALA), a serious medical condition leading to high mortality." | 8.93 | Metformin associated lactic acidosis (MALA): clinical profiling and management. ( Coclite, D; Manzione, A; Maresca, B; Menè, P; Moioli, A; Napoletano, AM; Pirozzi, N; Punzo, G, 2016) |
| "This study aimed at comparing the effects of metformin on tubulointerstitial fibrosis (TIF) in different stages of diabetic nephropathy (DN) in vivo and evaluating the mechanism in high glucose (HG)-treated renal tubular epithelial cells (RTECs) in vitro." | 8.02 | Metformin attenuates renal tubulointerstitial fibrosis via upgrading autophagy in the early stage of diabetic nephropathy. ( Shi, K; Sun, D; Sun, H; Wang, F; Zhang, C; Zhang, X; Zuo, B, 2021) |
| "To compare the risk of lactic acidosis hospitalization between patients treated with metformin versus sulfonylureas following development of reduced kidney function." | 7.96 | Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas. ( Chipman, J; Chu, PY; Elasy, T; Greevy, RA; Griffin, MR; Grijalva, CG; Hackstadt, AJ; Hung, AM; Roumie, CL, 2020) |
| "Metformin attenuates diabetes-induced renal medullary tissue hypoxia in an animal model of insulinopenic type 1 diabetes." | 7.91 | Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2. ( Christensen, M; Gustafsson, H; Krag, SP; Nørregaard, R; Palm, F; Schiffer, TA, 2019) |
| "Metformin is renally excreted and has been associated with the development of lactic acidosis." | 7.85 | Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. ( Connelly, PJ; Donnelly, L; Lonergan, M; Pearson, ER; Soto-Pedre, E; Zhou, K, 2017) |
| "We report a case of metformin-associated lactic acidosis (MALA) in a 66-year-old man with end-stage renal disease on peritoneal dialysis (PD)." | 7.83 | Peritoneal dialysis treatment of metformin-associated lactic acidosis in a diabetic nephropathy patient . ( Gao, J; Gu, Z; Na, Y; Xu, Y, 2016) |
| "To determine whether the use of metformin in type 2 diabetic patients with various kidney functions is associated with an increased risk of lactic acidosis (LA)." | 7.80 | Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. ( Corvino, FA; Gottwald-Hostalek, U; Guedes, S; Richy, FF; Sabidó-Espin, M, 2014) |
| "The reported incidence of metformin associated lactic acidosis (MALA) in type 2 diabetes mellitus (DM) is 3-9 cases per 100,000 patient-years." | 7.77 | Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. ( Doorenbos, CJ; van Berlo-van de Laar, IR; Vermeij, CG, 2011) |
| "We suspect that the life-threatening complication of metformin-associated lactic acidosis, solely due to drug accumulation following renal impairment, occurs more frequently than that previously reported and is not necessarily associated with other predisposing factors for lactic acidosis." | 7.74 | Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? ( Felix, SB; Friesecke, S; Mayerle, J; Robinson, D; Roser, M; Runge, S; Warnke, C, 2008) |
| "Lactic acidosis is a recognised complication of the antihyperglycaemic biguanide agent metformin, especially in patients with renal failure." | 7.72 | Unexpected survival from severe metformin-associated lactic acidosis. ( de Gooijer, A; Schure, PJ; van Zanten, AR, 2003) |
| "The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance." | 7.70 | Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. ( Buysschaert, M; Dramais, AS; Hermans, MP; Wallemacq, PE, 2000) |
| "To determine the respective role of metformin accumulation and tissue hypoxia in triggering metformin-associated lactic acidosis (MALA), we measured plasma (PM) and red blood cell (RM) metformin concentrations in 14 patients with MALA and in 58 diabetic patients on well-tolerated chronic metformin treatment." | 7.69 | Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis. ( De Cagny, B; Fournier, A; Lacroix, C; Lalau, JD, 1994) |
| "In recent years, lactic acidosis has been described in association with metformin therapy in diabetics." | 7.66 | Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. ( Casey, C; Hermann, LS; Magnusson, S; Möller, B; Tucker, GT; Woods, HF, 1981) |
| "Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes mellitus (T2DM), acting via indirect activation of 5' Adenosine monophosphate-activated Protein Kinase (AMPK)." | 6.72 | Mechanism and application of metformin in kidney diseases: An update. ( Meng, X; Song, A; Zhang, C, 2021) |
| " Future clinical trials are necessary to study the nephroprotective effects of the combined treatment at a low dosage in patients with diabetes." | 6.44 | Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats. ( Htun, KT; Jaikumkao, K; Kothan, S; Lungkaphin, A; Montha, N; Pengrattanachot, N; Phengpol, N; Promsan, S; Sriburee, S; Sutthasupha, P; Thongnak, L, 2024) |
| "Prediabetes was induced by exposing male Sprague Dawley rats (150-180 g) to high-fat high- carbohydrate (HFHC) diet for 20 weeks." | 5.62 | Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model. ( Gamede, M; Khathi, A; Mabuza, L; Ngubane, P, 2021) |
| " To describe a concentration range in clinical samples after chronic use of metformin, metformin serum concentrations were determined in serum samples of 95 diabetic patients receiving daily doses of 500mg-3000mg of metformin." | 5.48 | Range of therapeutic metformin concentrations in clinical blood samples and comparison to a forensic case with death due to lactic acidosis. ( Hess, C; Madea, B; Stratmann, B; Tschoepe, D; Unger, M, 2018) |
| "Numerous patients with type 2 diabetes have renal impairment, especially in the elderly population." | 5.39 | [How I treat ... with metformin a diabetic patient with moderate renal insufficiency]. ( Scheen, AJ, 2013) |
| "All-cause mortality, cardiovascular death, cardiovascular events (death, hospitalization for heart failure, myocardial infarction, stroke or myocardial ischemia), end stage renal disease (ESRD) and the kidney disease composite (ESRD or death) were compared in metformin users and non-users with diabetes and CKD enrolled in the Trial to Reduce Cardiovascular Events with Aranesp (darbepoeitin-alfa) Therapy (TREAT) (NCT00093015)." | 5.30 | Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. ( Burdmann, EA; Charytan, DM; Claggett, B; Cooper, ME; Eckardt, KU; Ivanovich, P; Levey, AS; Lewis, EF; Liu, J; McGill, JB; McMurray, JJV; Parfrey, P; Parving, HH; Pfeffer, MA; Remuzzi, G; Singh, AK; Solomon, SD; Weinrauch, LA, 2019) |
| " However, if used in excessive doses for patients with kidney disease, it will be contraindicated with side effects such as lactic acidosis." | 5.22 | Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease. ( Rahman, F; Tuba, S, 2022) |
| " Secondary goals examined albuminuria, age, race, sex, and metformin prescription." | 5.20 | Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease. ( Poretsky, L; Striker, GE; Vlassara, H; Woodward, M; Yubero-Serrano, EM, 2015) |
| "The aim of his study was to compare the efficacy of pioglitazone with metformin on the reduction of albuminuria in type 2 diabetic patients with hypertension and microalbuminuria treated with renin-angiotensin system inhibitors (RAS-Is)." | 5.15 | Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study. ( Haneda, M; Ishizeki, K; Itoh, H; Iwashima, Y; Miura, T; Morikawa, A; Muto, E; Oshima, E; Sekiguchi, M; Yokoyama, H, 2011) |
| "There is no evidence that the use of contrast media (CM) in diabetic patients with serum creatinine <130 μmole/L leads to metformin accumulation and subsequent lactic acidosis." | 5.15 | Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry. ( Al Babtain, MA; Al Taweel, ES; Al-Amri, HS; Al-Moghairi, AM; Aloudah, NM; Radwan, MA, 2011) |
| "Troglitazone ameliorated microalbuminuria in diabetic nephropathy." | 5.08 | Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. ( Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y, 1998) |
| "Metformin (MF) accumulation during acute kidney injury is associated with high anion gap lactic acidosis type B (MF-associated lactic acidosis, MALA), a serious medical condition leading to high mortality." | 4.93 | Metformin associated lactic acidosis (MALA): clinical profiling and management. ( Coclite, D; Manzione, A; Maresca, B; Menè, P; Moioli, A; Napoletano, AM; Pirozzi, N; Punzo, G, 2016) |
| " Recent studies demonstrated that hypoglycemic agents improving insulin resistance such as metformin and troglitazone reduce blood pressure." | 4.79 | [Treatment of hypertension associated with diabetes mellitus]. ( Katayama, S, 1997) |
| " Metformin and renin-angiotensin system blockers were negatively associated with albuminuria and chronic kidney disease stages (p < 0." | 4.02 | Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study. ( Abdulraheem, AM; Abufaraj, M; Al-Sabbagh, MQ; Albtoosh, A; Aljabiri, H; Arabiat, M; Farah, RI; Momani, MS, 2021) |
| "This study aimed at comparing the effects of metformin on tubulointerstitial fibrosis (TIF) in different stages of diabetic nephropathy (DN) in vivo and evaluating the mechanism in high glucose (HG)-treated renal tubular epithelial cells (RTECs) in vitro." | 4.02 | Metformin attenuates renal tubulointerstitial fibrosis via upgrading autophagy in the early stage of diabetic nephropathy. ( Shi, K; Sun, D; Sun, H; Wang, F; Zhang, C; Zhang, X; Zuo, B, 2021) |
| "To compare the risk of lactic acidosis hospitalization between patients treated with metformin versus sulfonylureas following development of reduced kidney function." | 3.96 | Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas. ( Chipman, J; Chu, PY; Elasy, T; Greevy, RA; Griffin, MR; Grijalva, CG; Hackstadt, AJ; Hung, AM; Roumie, CL, 2020) |
| " The secondary outcome was metformin-associated lactic acidosis." | 3.96 | The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. ( An, JN; Kim, CT; Kim, DK; Kim, YC; Kim, YS; Kwon, S; Lee, J; Lee, JP; Lim, CS; Oh, S; Oh, YK; Park, JY; Park, S, 2020) |
| "Metformin attenuates diabetes-induced renal medullary tissue hypoxia in an animal model of insulinopenic type 1 diabetes." | 3.91 | Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2. ( Christensen, M; Gustafsson, H; Krag, SP; Nørregaard, R; Palm, F; Schiffer, TA, 2019) |
| "Metformin is renally excreted and has been associated with the development of lactic acidosis." | 3.85 | Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study. ( Connelly, PJ; Donnelly, L; Lonergan, M; Pearson, ER; Soto-Pedre, E; Zhou, K, 2017) |
| "We report a case of metformin-associated lactic acidosis (MALA) in a 66-year-old man with end-stage renal disease on peritoneal dialysis (PD)." | 3.83 | Peritoneal dialysis treatment of metformin-associated lactic acidosis in a diabetic nephropathy patient . ( Gao, J; Gu, Z; Na, Y; Xu, Y, 2016) |
| " Thus, in patients with diabetes-associated chronic kidney disease, the glucose lowering therapy has to account for renal function to avoid hypoglycemic episodes and other side effects such as lactic acidosis due to metformin." | 3.83 | [New aspects in prevention and therapy of diabetic nephropathy]. ( Böger, CA; Büttner, R; Rheinberger, M, 2016) |
| "The role of metformin in the development of lactic acidosis (LA) in the setting of acute renal failure (ARF) is debated." | 3.83 | Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study. ( Angelini, C; Badalamenti, S; Calvetta, A; Cucchiari, D; Merizzoli, E; Morenghi, E; Podestà, MA; Ponticelli, C, 2016) |
| " Metformin - an oral hypoglycemic drug universally recommended as the first-line treatment for type 2 diabetes mellitus (T2DM) - undergoes significant accumulation in advanced CKD that may ultimately lead to lactic acidosis." | 3.81 | Prescription-medication sharing among family members: an unrecognized cause of a serious drug adverse event in a patient with impaired renal function. ( Makówka, A; Nowicki, M; Zawiasa, A, 2015) |
| "To determine whether the use of metformin in type 2 diabetic patients with various kidney functions is associated with an increased risk of lactic acidosis (LA)." | 3.80 | Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. ( Corvino, FA; Gottwald-Hostalek, U; Guedes, S; Richy, FF; Sabidó-Espin, M, 2014) |
| "The reported incidence of metformin associated lactic acidosis (MALA) in type 2 diabetes mellitus (DM) is 3-9 cases per 100,000 patient-years." | 3.77 | Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. ( Doorenbos, CJ; van Berlo-van de Laar, IR; Vermeij, CG, 2011) |
| "We suspect that the life-threatening complication of metformin-associated lactic acidosis, solely due to drug accumulation following renal impairment, occurs more frequently than that previously reported and is not necessarily associated with other predisposing factors for lactic acidosis." | 3.74 | Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? ( Felix, SB; Friesecke, S; Mayerle, J; Robinson, D; Roser, M; Runge, S; Warnke, C, 2008) |
| "The objective of the study was to describe the clinical and biochemical findings of four patients with chronic hypothyroidism, previously euthyroid on fixed doses of L-T4 for several years, in whom the metformin was initiated." | 3.73 | Thyrotropin suppression by metformin. ( Filmore-Nassar, A; Glass, AR; Vigersky, RA, 2006) |
| "Lactic acidosis is a recognised complication of the antihyperglycaemic biguanide agent metformin, especially in patients with renal failure." | 3.72 | Unexpected survival from severe metformin-associated lactic acidosis. ( de Gooijer, A; Schure, PJ; van Zanten, AR, 2003) |
| "The aim of this study was to determine the distribution of plasma total homocysteine (tHcy) concentrations in type 2 diabetic patients and to assess whether high tHcy values were related to chronic complications (particularly macroangiopathy and nephropathy) and/or the degree of insulin resistance." | 3.70 | Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance. ( Buysschaert, M; Dramais, AS; Hermans, MP; Wallemacq, PE, 2000) |
| "Recently, concern has been expressed about the hazards of lactic acidosis following the use of intravascular iodinated contrast agents in patients taking metformin." | 3.70 | Clinical risk associated with contrast angiography in metformin treated patients: a clinical review. ( Chan, P; Cleveland, T; Gaines, PA; Nawaz, S, 1998) |
| "Treatment with metformin is occasionally associated with the development of severe lactic acidosis." | 3.69 | Contraindications to metformin therapy in patients with NIDDM. ( Bosman, D; Krentz, AJ; Sulkin, TV, 1997) |
| "To determine the respective role of metformin accumulation and tissue hypoxia in triggering metformin-associated lactic acidosis (MALA), we measured plasma (PM) and red blood cell (RM) metformin concentrations in 14 patients with MALA and in 58 diabetic patients on well-tolerated chronic metformin treatment." | 3.69 | Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis. ( De Cagny, B; Fournier, A; Lacroix, C; Lalau, JD, 1994) |
| "In recent years, lactic acidosis has been described in association with metformin therapy in diabetics." | 3.66 | Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function. ( Casey, C; Hermann, LS; Magnusson, S; Möller, B; Tucker, GT; Woods, HF, 1981) |
| "The renal hemodynamics profile of such combination therapies has not been evaluated in detail." | 3.01 | Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine. ( Bosch, A; Bramlage, P; Jung, S; Kannenkeril, D; Kolwelter, J; Korn, M; Ott, C; Schiffer, M; Schmieder, RE; Striepe, K, 2021) |
| "Therefore, we compared the renal hemodynamic effects of dapagliflozin with gliclazide in type 2 diabetes." | 2.94 | The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. ( Bozovic, A; Danser, AHJ; Emanuel, AL; Geurts, F; Hoorn, EJ; Joles, JA; Kramer, MHH; Larsen, EL; Muskiet, MHA; Nieuwdorp, M; Poulsen, HE; Smits, MM; Tonneijck, L; Touw, DJ; van Baar, MJB; van Bommel, EJM; van Raalte, DH, 2020) |
| "The Treatment Options for type 2 Diabetes in Adolescent and Youth study, a randomized clinical trial of three treatments for type 2 diabetes (T2DM) in youth, demonstrated treatment failure (defined as sustained HbA1c ≥8%, or inability to wean insulin after 3 months after acute metabolic decomposition) in over half of the participants." | 2.94 | Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study. ( Bacha, F; Braffett, BH; Gidding, SS; Gubitosi-Klug, RA; Levitt Katz, LE; Shah, AS; Shah, RD; Tryggestad, JB; Urbina, EM, 2020) |
| "Glucose-lowering treatment options for type 2 diabetes mellitus patients with chronic kidney disease are limited." | 2.80 | Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease. ( Crowe, S; McGill, JB; von Eynatten, M; Woerle, HJ; Yki-Järvinen, H, 2015) |
| "Metformin is an oral antihyperglycemic drug widely used to treat type 2 diabetes mellitus (T2DM), acting via indirect activation of 5' Adenosine monophosphate-activated Protein Kinase (AMPK)." | 2.72 | Mechanism and application of metformin in kidney diseases: An update. ( Meng, X; Song, A; Zhang, C, 2021) |
| "Metformin is a glucose-lowering agent that is used as a first-line therapy for type 2 diabetes (T2D)." | 2.66 | Significance of Metformin Use in Diabetic Kidney Disease. ( Kawanami, D; Takashi, Y; Tanabe, M, 2020) |
| " Achieving and maintaining tight glycemic control is key to preventing development or progression of CKD; however, improving glycemic control may be limited by effects of renal impairment on the efficacy and safety of T2DM treatments, necessitating dosing adjustments and careful evaluation of contraindications." | 2.58 | Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers. ( Adler, S; Tong, L, 2018) |
| "Metformin was found to diminish apoptosis in different experimental renal settings." | 2.55 | Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy. ( Eisenreich, A; Leppert, U, 2017) |
| "Metformin is a first-line therapy in patients with Type 2 diabetes, as it appears to be effective in reducing diabetes related end points and mortality in overweight patients." | 2.55 | Could metformin be used in patients with diabetes and advanced chronic kidney disease? ( Abraham, G; Chowdhury, TA; Fan, SL; McCafferty, K; Oei, EL; Srirathan, D; Yaqoob, MM, 2017) |
| "One of the commonest complications of type 2 diabetes is renal disease." | 2.50 | Novel hypoglycaemic agents: considerations in patients with chronic kidney disease. ( Game, F, 2014) |
| "Type 2 diabetes mellitus is a troubling chronic disease and diabetic nephropathy is one of the most important complications of diabetes mellitus." | 2.49 | Bright renoprotective properties of metformin: beyond blood glucose regulatory effects. ( Ardalan, MR; Baradaran, A; Mardani, S; Momeni, A; Nasri, H; Rafieian-Kopaei, M, 2013) |
| " Future clinical trials are necessary to study the nephroprotective effects of the combined treatment at a low dosage in patients with diabetes." | 2.44 | Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats. ( Htun, KT; Jaikumkao, K; Kothan, S; Lungkaphin, A; Montha, N; Pengrattanachot, N; Phengpol, N; Promsan, S; Sriburee, S; Sutthasupha, P; Thongnak, L, 2024) |
| "The biguanides are a class of oral hypoglycemic agents that are commonly used in the treatment of diabetes mellitus." | 2.38 | Biguanide-associated lactic acidosis. Case report and review of the literature. ( Arieff, AI; Barr, J; Gan, SC; Pearl, RG, 1992) |
| "Gallic acid is a type of phenolic acid that has been shown to be a potential drug candidate to treat diabetic kidney disease, an important complication of diabetes." | 1.91 | Gallic acid improves the metformin effects on diabetic kidney disease in mice. ( Hong, Y; Sun, W; Wang, J; Xu, X; Zhang, K; Zhang, L, 2023) |
| "7,200 patients with type 2 diabetes mellitus were enrolled." | 1.72 | Quality of care and prescription patterns among patients with diabetic kidney disease-a large-scale cohort study from Taiwanese clinics. ( Chen, ML; Chen, S; Chou, CW; Lee, YJ; Tsai, KY; Tzeng, TF, 2022) |
| " Chronic adenine dosing resulted in severe CKD in vehicle-treated rats as indicated by a marked rise in serum creatinine levels, a marked decrease in creatinine clearance, and a disturbed mineral metabolism." | 1.72 | Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats. ( Corremans, R; D'Haese, PC; De Broe, ME; Leysen, H; Maudsley, S; Neven, E; Verhulst, A; Vervaet, BA, 2022) |
| "A total of 1086 patients with type 2 diabetes were included." | 1.72 | Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective. ( Bai, J; Cheng, X; Dong, LM; Liu, J; Luo, SQ; Song, ZH; Wang, XF; Wang, XL; Xu, SS; Zhang, C; Zhou, JB, 2022) |
| "Diabetic nephropathy is reported to occur as a result of the interactions between several pathophysiological disturbances, as well as renal oxidative stress and inflammation." | 1.62 | Malaysian Propolis and Metformin Synergistically Mitigate Kidney Oxidative Stress and Inflammation in Streptozotocin-Induced Diabetic Rats. ( Abu Bakar, AB; Jalil, NAC; Mohamed, M; Nna, VU; Othman, ZA; Zakaria, Z, 2021) |
| "This study was designed to investigate the efficacy and underlying mechanisms of HKC combined with metformin (MET), the first-line medication for treating type 2 diabetes, in the treatment of renal interstitial fibrosis." | 1.62 | Huangkui capsule in combination with metformin ameliorates diabetic nephropathy via the Klotho/TGF-β1/p38MAPK signaling pathway. ( Gu, LY; Tang, HT; Xu, ZX, 2021) |
| "The anti-diabetic nephropathy properties were systematically analyzed in the diabetic db/db mice treated with Met, BBR or with combination of Met and BBR." | 1.62 | Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation. ( Sun, G; Sun, X; Zhang, B; Zhang, C; Zhang, X, 2021) |
| "Prediabetes was induced by exposing male Sprague Dawley rats (150-180 g) to high-fat high- carbohydrate (HFHC) diet for 20 weeks." | 1.62 | Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model. ( Gamede, M; Khathi, A; Mabuza, L; Ngubane, P, 2021) |
| " Therefore, the present study investigated the protective effect of L-egt alone, or combined with metformin, on renal damage in a type-2 diabetic (T2D) rat model." | 1.62 | L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway. ( Channa, ML; Dare, A; Nadar, A, 2021) |
| "Metformin + ZY treatment significantly lowered blood glucose, water intake, urine total protein, urine albumin, urine volume, serum triglyceride, and serum cholesterol levels in the DN group." | 1.56 | Effects of HuoxueJiangtang decoction alone or in combination with metformin on renal function and renal cortical mRNA expression in diabetic nephropathy rats. ( Chu, S; Li, H; Liu, D; Liu, X; Qu, X; Shuai, Y; Zhang, X; Zhao, H, 2020) |
| "The global incidence and prevalence of type 2 diabetes have been escalating in recent decades." | 1.56 | 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. ( Chang, KC; Chao, TF; Chao, TH; Chen, WJ; Cheng, HM; Cheng, SM; Chiang, CE; Chu, PH; Huang, JL; Hung, HF; Hwang, JJ; Lai, WT; Li, YH; Lin, SJ; Lin, TH; Liu, ME; Liu, PY; Shyu, KG; Sung, SH; Tsai, CD; Ueng, KC; Wang, KL; Wu, YJ; Wu, YW; Yeh, HI; Yeh, SJ; Yin, WH, 2020) |
| "Metformin (MET) has protective effect on diabetic nephropathy (DN)." | 1.56 | Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-β1 axis. ( Liu, L; Sun, J; Xiang, P; Xu, J; Ye, S, 2020) |
| "Metformin is an anti-diabetic drug widely used for treating patients with type 2 diabetes." | 1.56 | Metformin reduces TRPC6 expression through AMPK activation and modulates cytoskeleton dynamics in podocytes under diabetic conditions. ( Angielski, S; Audzeyenka, I; Kreft, E; Piwkowska, A; Rachubik, P; Rogacka, D; Rychłowski, M; Szrejder, M, 2020) |
| "Metformin was withheld and signs and symptoms quickly resolved." | 1.48 | Metformin-induced encephalopathy: the role of thiamine. ( Bynevelt, M; Franconi, C; McGarvey, C; Prentice, D, 2018) |
| " To describe a concentration range in clinical samples after chronic use of metformin, metformin serum concentrations were determined in serum samples of 95 diabetic patients receiving daily doses of 500mg-3000mg of metformin." | 1.48 | Range of therapeutic metformin concentrations in clinical blood samples and comparison to a forensic case with death due to lactic acidosis. ( Hess, C; Madea, B; Stratmann, B; Tschoepe, D; Unger, M, 2018) |
| "Diabetic nephropathy is one of the most common and serious complications of diabetes mellitus." | 1.48 | Ameliorative effects of protodioscin on experimental diabetic nephropathy. ( Dong, Y; Guo, C; Liu, Y; Xie, G; Zhu, H, 2018) |
| "A recent study of advanced diabetic kidney disease patients in Taiwan in Lancet Endocrinology and Diabetes has provided unique insight into the potential consequences of unrestricted metformin use, including a 35% higher adjusted mortality risk that was dose-dependent." | 1.46 | Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. ( Kalantar-Zadeh, K; Kovesdy, CP; Rhee, CM, 2017) |
| "Geniposide (GPO) was previously demonstrated to modulate glucose metabolism in diabetes." | 1.46 | Geniposide reduces development of streptozotocin-induced diabetic nephropathy via regulating nuclear factor-kappa B signaling pathways. ( Chen, F; Hu, X; Jin, G; Shi, Z; Sun, W; Zhang, X, 2017) |
| " Given that lowering glucose is the first objective of diabetic patients, we also examined the effects of SAA combined with metformin (MET) on both complications." | 1.43 | Effects of the Nrf2 Protein Modulator Salvianolic Acid A Alone or Combined with Metformin on Diabetes-associated Macrovascular and Renal Injury. ( Du, GH; He, YY; Hou, BY; Ma, LL; Niu, ZR; Pang, XC; Song, JK; Wu, P; Yan, Y; Yang, XY; Zhang, L, 2016) |
| "Metformin has been demonstrated to reduce apoptosis and albuminuria in type 2 diabetes." | 1.43 | Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions. ( Eisenreich, A; Kreutz, R; Langer, S, 2016) |
| "Hyperglycemia and hyperlipidemia directly affected the contractile function of VSMCs." | 1.42 | Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway. ( Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y, 2015) |
| "When metformin was added to the high glucose medium, the activity of SOD in supernatant fluid was increased significantly, whereas a significant reduction (P<0." | 1.42 | Metformin alleviates high glucose-mediated oxidative stress in rat glomerular mesangial cells by modulation of p38 mitogen-activated protein kinase expression in vitro. ( Gu, JF; Wang, S; Xiao, CC; Yang, D; Yao, XM; Ye, SD, 2015) |
| "Metformin eligibility was assessed among 3,902 adults with diabetes who participated in the 1999-2010 National Health and Nutrition Examination Surveys and reported routine access to health care, using conventional sCr thresholds (eligible if <1." | 1.42 | Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine. ( Grubbs, V; Hsu, CY; Lin, F; Powe, NR; Saran, R; Saydah, S; Shahinian, V; Shlipak, MG; Tuot, DS; Williams, DE; Yee, J, 2015) |
| " The place of metformin is of particular interest since most scientific societies now recommend using half the dosage in moderate RI and abstaining from use in severe RI, while the classic contraindication with RI has not been removed from the label." | 1.40 | How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study. ( Blicklé, JF; Dejager, S; Fiquet, B; Penfornis, A; Quéré, S, 2014) |
| "Diabetic nephropathy is associated with premature senescence." | 1.40 | AMPK-mediated downregulation of connexin43 and premature senescence of mesangial cells under high-glucose conditions. ( Cai, GY; Chen, XM; Cui, SY; Fu, B; Guo, YN; Hong, Q; Hu, X; Lv, Y; Wang, JC; Yin, Z, 2014) |
| "Numerous patients with type 2 diabetes have renal impairment, especially in the elderly population." | 1.39 | [How I treat ... with metformin a diabetic patient with moderate renal insufficiency]. ( Scheen, AJ, 2013) |
| "Metformin was independently associated with lower prevalence of cardiovascular disease for any age quartile and eGFR category than all other treatments." | 1.39 | Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study. ( Bonora, E; Cavalot, F; Cignarelli, M; Ferrannini, E; Fondelli, C; Morano, S; Orsi, E; Penno, G; Pugliese, G; Solini, A; Trevisan, R; Vedovato, M, 2013) |
| "Diabetic nephropathy is a major cause of morbidity and mortality in diabetic patients." | 1.38 | Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats. ( Abd el-Latif, FF; Khalifa, M; Sayed, AA, 2012) |
| "Approximately 40% of patients with type 2 diabetes may progress to nephropathy and a good metabolic control can prevent the development of diabetic renal injury." | 1.37 | Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats. ( da Cunha, FX; Louro, TM; Matafome, PN; Nunes, EC; Seiça, RM, 2011) |
| "On the other hand, treatment of diabetic nephropathy rats with metformin normalized all biochemical changes and the energy status in kidney tissues." | 1.37 | Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression. ( Alhaider, AA; Kfoury, H; Korashy, HM; Mansour, MA; Mobark, M; Sayed-Ahmed, MM, 2011) |
| "Renal hypertrophy in rats with Type 1 diabetes was associated with reduction in AMPK phosphorylation and increased mTOR activity." | 1.34 | A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. ( Choudhury, GG; Feliers, D; Foretz, M; Kasinath, BS; Lee, MJ; Mahimainathan, L; Mariappan, MM; Musi, N; Sataranatarajan, K; Viollet, B; Weinberg, JM, 2007) |
| "Of 19,981 patients with Type 2 diabetes, 11,297 were taking metformin in accordance with our current guideline." | 1.34 | Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. ( McKnight, JA; Strachan, MW; Warren, RE; Wild, S, 2007) |
| "Treatment with fenofibrate or metformin ameliorated renal damage in OLETF rats through SREBP-1 and some enzyme regulated by it reduced fat deposit in kidney directly." | 1.33 | [Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney]. ( Guo, XH; Wang, NH; Wang, W; Wu, HH; Xu, XS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (1.68) | 18.7374 |
| 1990's | 9 (5.03) | 18.2507 |
| 2000's | 22 (12.29) | 29.6817 |
| 2010's | 94 (52.51) | 24.3611 |
| 2020's | 51 (28.49) | 2.80 |
| Authors | Studies |
|---|---|
| Tang, S | 1 |
| Wang, C | 1 |
| Li, YH | 2 |
| Niu, TY | 1 |
| Zhang, YH | 1 |
| Pang, YD | 1 |
| Wang, YX | 1 |
| Kong, WJ | 1 |
| Song, DQ | 1 |
| Zhang, X | 6 |
| Chen, H | 1 |
| Lei, Y | 1 |
| Xu, L | 1 |
| Liu, W | 1 |
| Fan, Z | 1 |
| Ma, Z | 1 |
| Yin, Z | 2 |
| Li, L | 2 |
| Zhu, C | 1 |
| Ma, B | 1 |
| Ott, C | 1 |
| Jung, S | 1 |
| Korn, M | 1 |
| Kannenkeril, D | 1 |
| Bosch, A | 1 |
| Kolwelter, J | 1 |
| Striepe, K | 1 |
| Bramlage, P | 1 |
| Schiffer, M | 1 |
| Schmieder, RE | 1 |
| Zhang, B | 2 |
| Zhang, C | 5 |
| Sun, G | 1 |
| Sun, X | 1 |
| Song, Y | 1 |
| Guo, F | 1 |
| Liu, Y | 3 |
| Huang, F | 1 |
| Fan, X | 1 |
| Zhao, L | 2 |
| Qin, G | 1 |
| Corremans, R | 2 |
| Neven, E | 1 |
| Maudsley, S | 1 |
| Leysen, H | 1 |
| De Broe, ME | 2 |
| D'Haese, PC | 2 |
| Vervaet, BA | 2 |
| Verhulst, A | 2 |
| Zhang, Z | 2 |
| Dong, H | 1 |
| Chen, J | 1 |
| Yin, M | 1 |
| Liu, F | 2 |
| Song, ZH | 1 |
| Wang, XL | 1 |
| Wang, XF | 1 |
| Liu, J | 3 |
| Luo, SQ | 1 |
| Xu, SS | 1 |
| Cheng, X | 1 |
| Bai, J | 1 |
| Dong, LM | 1 |
| Zhou, JB | 1 |
| Tsai, KY | 1 |
| Chen, S | 1 |
| Chou, CW | 1 |
| Tzeng, TF | 1 |
| Lee, YJ | 1 |
| Chen, ML | 1 |
| Rahman, F | 1 |
| Tuba, S | 1 |
| Syed, YY | 3 |
| Mohammad, HMF | 2 |
| Galal Gouda, S | 2 |
| Eladl, MA | 2 |
| Elkazaz, AY | 2 |
| Elbayoumi, KS | 2 |
| Farag, NE | 2 |
| Elshormilisy, A | 2 |
| Al-Ammash, BB | 2 |
| Hegazy, A | 2 |
| Abdelkhalig, SM | 2 |
| Mohamed, AS | 2 |
| El-Dosoky, M | 2 |
| Zaitone, SA | 2 |
| Tommerdahl, KL | 1 |
| Kula, AJ | 1 |
| Bjornstad, P | 1 |
| Dams, G | 1 |
| Kleibert, M | 1 |
| Zygmunciak, P | 1 |
| Łakomska, K | 1 |
| Mila, K | 1 |
| Zgliczyński, W | 1 |
| Mrozikiewicz-Rakowska, B | 1 |
| Hong, Y | 1 |
| Wang, J | 1 |
| Sun, W | 2 |
| Zhang, L | 2 |
| Xu, X | 2 |
| Zhang, K | 1 |
| Jaikumkao, K | 1 |
| Thongnak, L | 1 |
| Htun, KT | 1 |
| Pengrattanachot, N | 1 |
| Phengpol, N | 1 |
| Sutthasupha, P | 1 |
| Promsan, S | 1 |
| Montha, N | 1 |
| Sriburee, S | 1 |
| Kothan, S | 1 |
| Lungkaphin, A | 1 |
| Flory, JH | 1 |
| Hennessy, S | 1 |
| Bailey, CJ | 1 |
| Inzucchi, SE | 2 |
| Ren, H | 1 |
| Shao, Y | 1 |
| Wu, C | 1 |
| Ma, X | 1 |
| Lv, C | 1 |
| Wang, Q | 1 |
| Gosmanova, EO | 1 |
| Shahzad, SR | 1 |
| Sumida, K | 1 |
| Kovesdy, CP | 2 |
| Gosmanov, AR | 1 |
| Szrejder, M | 1 |
| Rachubik, P | 1 |
| Rogacka, D | 2 |
| Audzeyenka, I | 2 |
| Rychłowski, M | 1 |
| Kreft, E | 1 |
| Angielski, S | 2 |
| Piwkowska, A | 2 |
| van Bommel, EJM | 1 |
| Muskiet, MHA | 1 |
| van Baar, MJB | 1 |
| Tonneijck, L | 1 |
| Smits, MM | 1 |
| Emanuel, AL | 1 |
| Bozovic, A | 1 |
| Danser, AHJ | 1 |
| Geurts, F | 1 |
| Hoorn, EJ | 1 |
| Touw, DJ | 1 |
| Larsen, EL | 1 |
| Poulsen, HE | 1 |
| Kramer, MHH | 1 |
| Nieuwdorp, M | 1 |
| Joles, JA | 1 |
| van Raalte, DH | 1 |
| Zhao, Y | 1 |
| Sun, M | 1 |
| Jiang, X | 1 |
| Ruan, XL | 1 |
| Xue, YX | 1 |
| Yang, S | 3 |
| Shi, M | 1 |
| Wang, LN | 1 |
| Kwon, S | 2 |
| Kim, YC | 1 |
| Park, JY | 1 |
| Lee, J | 1 |
| An, JN | 1 |
| Kim, CT | 2 |
| Oh, S | 1 |
| Park, S | 1 |
| Kim, DK | 1 |
| Oh, YK | 1 |
| Kim, YS | 1 |
| Lim, CS | 1 |
| Lee, JP | 2 |
| Packer, M | 1 |
| Gabriel, R | 1 |
| Boukichou Abdelkader, N | 1 |
| Acosta, T | 1 |
| Gilis-Januszewska, A | 1 |
| Gómez-Huelgas, R | 1 |
| Makrilakis, K | 1 |
| Kamenov, Z | 1 |
| Paulweber, B | 1 |
| Satman, I | 1 |
| Djordjevic, P | 1 |
| Alkandari, A | 1 |
| Mitrakou, A | 1 |
| Lalic, N | 1 |
| Colagiuri, S | 1 |
| Lindström, J | 1 |
| Egido, J | 1 |
| Natali, A | 1 |
| Pastor, JC | 1 |
| Teuschl, Y | 1 |
| Lind, M | 1 |
| Silva, L | 1 |
| López-Ridaura, R | 1 |
| Tuomilehto, J | 1 |
| Chu, PY | 1 |
| Hackstadt, AJ | 1 |
| Chipman, J | 1 |
| Griffin, MR | 2 |
| Hung, AM | 2 |
| Greevy, RA | 2 |
| Grijalva, CG | 2 |
| Elasy, T | 1 |
| Roumie, CL | 2 |
| Xu, J | 1 |
| Xiang, P | 1 |
| Liu, L | 1 |
| Sun, J | 1 |
| Ye, S | 2 |
| Sekar, V | 1 |
| Mani, S | 1 |
| Malarvizhi, R | 1 |
| Barathidasan, R | 1 |
| Vasanthi, HR | 1 |
| Awal, HB | 1 |
| Nandula, SR | 1 |
| Domingues, CC | 1 |
| Dore, FJ | 1 |
| Kundu, N | 1 |
| Brichacek, B | 1 |
| Fakhri, M | 1 |
| Elzarki, A | 1 |
| Ahmadi, N | 1 |
| Safai, S | 1 |
| Fosso, M | 1 |
| Amdur, RL | 1 |
| Sen, S | 1 |
| Kleinaki, Z | 1 |
| Kapnisi, S | 1 |
| Theodorelou-Charitou, SA | 1 |
| Nikas, IP | 1 |
| Paschou, SA | 1 |
| Tryggestad, JB | 1 |
| Shah, RD | 1 |
| Braffett, BH | 1 |
| Bacha, F | 1 |
| Gidding, SS | 1 |
| Gubitosi-Klug, RA | 1 |
| Shah, AS | 1 |
| Urbina, EM | 1 |
| Levitt Katz, LE | 1 |
| Kawanami, D | 1 |
| Takashi, Y | 1 |
| Tanabe, M | 1 |
| Chiang, CE | 1 |
| Ueng, KC | 1 |
| Chao, TH | 1 |
| Lin, TH | 1 |
| Wu, YJ | 1 |
| Wang, KL | 1 |
| Sung, SH | 1 |
| Yeh, HI | 1 |
| Liu, PY | 1 |
| Chang, KC | 1 |
| Shyu, KG | 1 |
| Huang, JL | 1 |
| Tsai, CD | 1 |
| Hung, HF | 1 |
| Liu, ME | 1 |
| Chao, TF | 1 |
| Cheng, SM | 1 |
| Cheng, HM | 1 |
| Chu, PH | 1 |
| Yin, WH | 1 |
| Wu, YW | 1 |
| Chen, WJ | 1 |
| Lai, WT | 1 |
| Lin, SJ | 1 |
| Yeh, SJ | 1 |
| Hwang, JJ | 1 |
| Fu, EL | 1 |
| van Diepen, M | 1 |
| Gao, Z | 1 |
| Kong, D | 1 |
| Cai, W | 1 |
| Zhang, J | 1 |
| Jia, L | 2 |
| Gu, LY | 1 |
| Tang, HT | 1 |
| Xu, ZX | 1 |
| Liu, X | 2 |
| Liu, D | 1 |
| Shuai, Y | 1 |
| Li, H | 1 |
| Zhao, H | 1 |
| Qu, X | 1 |
| Chu, S | 1 |
| Mostafa, DK | 1 |
| Khedr, MM | 1 |
| Barakat, MK | 1 |
| Abdellatif, AA | 1 |
| Elsharkawy, AM | 1 |
| Song, A | 1 |
| Meng, X | 1 |
| Omachi, K | 1 |
| Kaseda, S | 1 |
| Yokota, T | 1 |
| Kamura, M | 1 |
| Teramoto, K | 1 |
| Kuwazuru, J | 1 |
| Kojima, H | 1 |
| Nohara, H | 1 |
| Koyama, K | 1 |
| Ohtsuki, S | 1 |
| Misumi, S | 1 |
| Takeo, T | 1 |
| Nakagata, N | 1 |
| Li, JD | 1 |
| Shuto, T | 1 |
| Suico, MA | 1 |
| Miner, JH | 1 |
| Kai, H | 1 |
| Gamede, M | 1 |
| Mabuza, L | 1 |
| Ngubane, P | 1 |
| Khathi, A | 1 |
| Khokhar, M | 1 |
| Roy, D | 1 |
| Bajpai, NK | 1 |
| Bohra, GK | 1 |
| Yadav, D | 1 |
| Sharma, P | 1 |
| Purohit, P | 1 |
| Farah, RI | 1 |
| Al-Sabbagh, MQ | 1 |
| Momani, MS | 1 |
| Albtoosh, A | 1 |
| Arabiat, M | 1 |
| Abdulraheem, AM | 1 |
| Aljabiri, H | 1 |
| Abufaraj, M | 1 |
| Nna, VU | 1 |
| Abu Bakar, AB | 1 |
| Zakaria, Z | 1 |
| Othman, ZA | 1 |
| Jalil, NAC | 1 |
| Mohamed, M | 1 |
| Xing, L | 1 |
| Peng, F | 1 |
| Liang, Q | 1 |
| Dai, X | 1 |
| Ren, J | 1 |
| Wu, H | 1 |
| Zhu, Y | 2 |
| Zhao, S | 1 |
| Dare, A | 1 |
| Channa, ML | 1 |
| Nadar, A | 1 |
| Wang, F | 1 |
| Sun, H | 1 |
| Zuo, B | 1 |
| Shi, K | 1 |
| Sun, D | 1 |
| Eisenreich, A | 2 |
| Leppert, U | 1 |
| Connelly, PJ | 1 |
| Lonergan, M | 1 |
| Soto-Pedre, E | 1 |
| Donnelly, L | 1 |
| Zhou, K | 1 |
| Pearson, ER | 1 |
| Han, Y | 1 |
| Song, P | 1 |
| Hu, C | 1 |
| Xiao, L | 1 |
| Zhang, H | 1 |
| Sun, L | 1 |
| Tavares Bello, C | 1 |
| Castro Fonseca, R | 1 |
| Sousa Santos, F | 1 |
| Sequeira Duarte, J | 1 |
| Azinheira, J | 1 |
| Vasconcelos, C | 1 |
| El-Ashmawy, NE | 1 |
| Khedr, EG | 1 |
| El-Bahrawy, HA | 1 |
| El-Berashy, SA | 1 |
| McGarvey, C | 1 |
| Franconi, C | 1 |
| Prentice, D | 1 |
| Bynevelt, M | 1 |
| Hess, C | 1 |
| Unger, M | 1 |
| Madea, B | 1 |
| Stratmann, B | 1 |
| Tschoepe, D | 1 |
| Tong, L | 1 |
| Adler, S | 1 |
| Xing, Y | 1 |
| Chen, Y | 1 |
| Fan, A | 1 |
| Xu, Z | 1 |
| Jiang, W | 1 |
| Henry, RR | 1 |
| Frias, JP | 1 |
| Walsh, B | 1 |
| Skare, S | 1 |
| Hemming, J | 1 |
| Burns, C | 1 |
| Bicsak, TA | 1 |
| Baron, A | 1 |
| Fineman, M | 1 |
| Christensen, M | 1 |
| Schiffer, TA | 1 |
| Gustafsson, H | 1 |
| Krag, SP | 1 |
| Nørregaard, R | 1 |
| Palm, F | 1 |
| Guo, C | 1 |
| Dong, Y | 1 |
| Zhu, H | 1 |
| Xie, G | 1 |
| Charytan, DM | 1 |
| Solomon, SD | 1 |
| Ivanovich, P | 1 |
| Remuzzi, G | 1 |
| Cooper, ME | 1 |
| McGill, JB | 2 |
| Parving, HH | 1 |
| Parfrey, P | 1 |
| Singh, AK | 1 |
| Burdmann, EA | 1 |
| Levey, AS | 1 |
| Eckardt, KU | 1 |
| McMurray, JJV | 1 |
| Weinrauch, LA | 1 |
| Claggett, B | 1 |
| Lewis, EF | 1 |
| Pfeffer, MA | 1 |
| Fonseca, V | 1 |
| Kang, Z | 1 |
| Zeng, J | 1 |
| Zhang, T | 1 |
| Lin, S | 1 |
| Gao, J | 2 |
| Jiang, C | 1 |
| Fan, R | 1 |
| Yin, D | 1 |
| Xue, J | 1 |
| Wang, L | 1 |
| Sun, Z | 1 |
| Xing, C | 1 |
| Akinnuga, AM | 1 |
| Bamidele, O | 1 |
| Adewumi, AJ | 1 |
| Lehtonen, S | 1 |
| Kidokoro, K | 1 |
| Satoh, M | 1 |
| Channon, KM | 1 |
| Yada, T | 1 |
| Sasaki, T | 1 |
| Kashihara, N | 1 |
| Süfke, S | 1 |
| Steinhoff, J | 1 |
| Schütt, M | 1 |
| Scheen, AJ | 2 |
| Solini, A | 1 |
| Penno, G | 1 |
| Bonora, E | 1 |
| Fondelli, C | 1 |
| Orsi, E | 1 |
| Trevisan, R | 1 |
| Vedovato, M | 1 |
| Cavalot, F | 1 |
| Cignarelli, M | 1 |
| Morano, S | 1 |
| Ferrannini, E | 1 |
| Pugliese, G | 1 |
| Burgmann, K | 1 |
| Fatio, S | 1 |
| Jordi, B | 1 |
| Rutishauser, J | 1 |
| Ahmadi, F | 1 |
| Mohebi-Nejad, A | 1 |
| Nasri, H | 1 |
| Baradaran, A | 1 |
| Ardalan, MR | 1 |
| Mardani, S | 1 |
| Momeni, A | 1 |
| Rafieian-Kopaei, M | 1 |
| Guo, YN | 1 |
| Wang, JC | 1 |
| Cai, GY | 1 |
| Hu, X | 3 |
| Cui, SY | 1 |
| Lv, Y | 1 |
| Fu, B | 1 |
| Hong, Q | 1 |
| Chen, XM | 1 |
| Game, F | 1 |
| Lalau, JD | 3 |
| Arnouts, P | 1 |
| Sharif, A | 1 |
| Makówka, A | 1 |
| Zawiasa, A | 1 |
| Nowicki, M | 1 |
| Jankowski, M | 1 |
| Richy, FF | 1 |
| Sabidó-Espin, M | 1 |
| Guedes, S | 1 |
| Corvino, FA | 1 |
| Gottwald-Hostalek, U | 1 |
| Penfornis, A | 1 |
| Blicklé, JF | 1 |
| Fiquet, B | 1 |
| Quéré, S | 1 |
| Dejager, S | 1 |
| Takiyama, Y | 2 |
| Haneda, M | 3 |
| Venos, ES | 1 |
| Sigal, RJ | 1 |
| Li, T | 1 |
| Yang, GM | 1 |
| Wu, Y | 1 |
| Chen, XY | 1 |
| Lan, D | 1 |
| Tian, KL | 1 |
| Liu, LM | 1 |
| Cheng, L | 1 |
| Meng, XB | 1 |
| Lu, S | 1 |
| Wang, TT | 1 |
| Sun, GB | 1 |
| Sun, XB | 1 |
| Yubero-Serrano, EM | 1 |
| Woodward, M | 1 |
| Poretsky, L | 1 |
| Vlassara, H | 1 |
| Striker, GE | 1 |
| Stiefelhagen, P | 2 |
| Almaleki, N | 1 |
| Ashraf, M | 1 |
| Hussein, MM | 1 |
| Mohiuddin, SA | 1 |
| Yao, XM | 1 |
| Ye, SD | 1 |
| Xiao, CC | 1 |
| Gu, JF | 1 |
| Yang, D | 1 |
| Wang, S | 1 |
| Zechmann, S | 1 |
| Douros, A | 1 |
| Ebert, N | 1 |
| Jakob, O | 1 |
| Martus, P | 1 |
| Kreutz, R | 2 |
| Schaeffner, E | 1 |
| Pandya, KG | 1 |
| Budhram, R | 1 |
| Clark, GJ | 1 |
| Lau-Cam, CA | 1 |
| Yki-Järvinen, H | 1 |
| Crowe, S | 1 |
| Woerle, HJ | 1 |
| von Eynatten, M | 1 |
| Fath, R | 1 |
| Kim, DI | 1 |
| Park, MJ | 1 |
| Heo, YR | 1 |
| Park, SH | 1 |
| Tuot, DS | 1 |
| Lin, F | 1 |
| Shlipak, MG | 1 |
| Grubbs, V | 1 |
| Hsu, CY | 1 |
| Yee, J | 1 |
| Shahinian, V | 1 |
| Saran, R | 1 |
| Saydah, S | 1 |
| Williams, DE | 1 |
| Powe, NR | 1 |
| Kajbaf, F | 1 |
| Bennis, Y | 1 |
| Hurtel-Lemaire, AS | 1 |
| Andréjak, M | 1 |
| Christiansen, CF | 1 |
| Ehrenstein, V | 1 |
| Heide-Jørgensen, U | 1 |
| Skovbo, S | 1 |
| Nørrelund, H | 1 |
| Sørensen, HT | 1 |
| Jick, S | 1 |
| Bloomgarden, Z | 1 |
| Alscher, MD | 1 |
| Langer, S | 1 |
| Castelino, RL | 1 |
| Peterson, G | 1 |
| Moioli, A | 1 |
| Maresca, B | 1 |
| Manzione, A | 1 |
| Napoletano, AM | 1 |
| Coclite, D | 1 |
| Pirozzi, N | 1 |
| Punzo, G | 1 |
| Menè, P | 1 |
| Cucchiari, D | 1 |
| Podestà, MA | 1 |
| Merizzoli, E | 1 |
| Calvetta, A | 1 |
| Morenghi, E | 1 |
| Angelini, C | 1 |
| Ponticelli, C | 1 |
| Badalamenti, S | 1 |
| Rheinberger, M | 1 |
| Büttner, R | 1 |
| Böger, CA | 1 |
| Du, M | 1 |
| Kou, L | 1 |
| van Dalem, J | 1 |
| Brouwers, MC | 1 |
| Stehouwer, CD | 1 |
| Krings, A | 1 |
| Leufkens, HG | 1 |
| Driessen, JH | 1 |
| de Vries, F | 1 |
| Burden, AM | 1 |
| Wu, P | 1 |
| Yan, Y | 1 |
| Ma, LL | 1 |
| Hou, BY | 1 |
| He, YY | 1 |
| Niu, ZR | 1 |
| Song, JK | 1 |
| Pang, XC | 1 |
| Yang, XY | 1 |
| Du, GH | 1 |
| Gu, Z | 1 |
| Xu, Y | 1 |
| Na, Y | 1 |
| Jin, G | 1 |
| Shi, Z | 1 |
| Chen, F | 1 |
| Ravindran, S | 1 |
| Kuruvilla, V | 1 |
| Wilbur, K | 1 |
| Munusamy, S | 1 |
| Chowdhury, TA | 1 |
| Srirathan, D | 1 |
| Abraham, G | 1 |
| Oei, EL | 1 |
| Fan, SL | 1 |
| McCafferty, K | 1 |
| Yaqoob, MM | 1 |
| Pecoits-Filho, R | 1 |
| Fortes, J | 1 |
| Volaco, A | 1 |
| Vencio, S | 1 |
| Sposito, AC | 1 |
| Rhee, CM | 1 |
| Kalantar-Zadeh, K | 1 |
| Pourfarjam, Y | 1 |
| Rezagholizadeh, L | 1 |
| Nowrouzi, A | 1 |
| Meysamie, A | 1 |
| Ghaseminejad, S | 1 |
| Ziamajidi, N | 1 |
| Norouzi, D | 1 |
| Sauriasari, R | 1 |
| Wulandari, F | 1 |
| Nurifahmi, R | 1 |
| Sekar, AP | 1 |
| Susilo, VY | 1 |
| Nistala, R | 1 |
| Raja, A | 1 |
| Pulakat, L | 1 |
| Jung, EY | 1 |
| Cho, HS | 1 |
| Seo, JW | 1 |
| Kim, DW | 1 |
| Kim, HJ | 1 |
| Chang, SH | 1 |
| Park, DJ | 1 |
| Pilmore, HL | 1 |
| Banerji, MA | 1 |
| Purkayastha, D | 1 |
| Francis, BH | 1 |
| Vasisht, KP | 1 |
| Chen, SC | 1 |
| Peng, Y | 1 |
| Bakris, GL | 2 |
| Louro, TM | 1 |
| Matafome, PN | 1 |
| Nunes, EC | 1 |
| da Cunha, FX | 1 |
| Seiça, RM | 1 |
| Harumi, T | 1 |
| Watanabe, J | 1 |
| Fujita, Y | 1 |
| Honjo, J | 1 |
| Shimizu, N | 1 |
| Makino, Y | 1 |
| Lachin, JM | 1 |
| Viberti, G | 1 |
| Zinman, B | 1 |
| Haffner, SM | 1 |
| Aftring, RP | 1 |
| Paul, G | 1 |
| Kravitz, BG | 1 |
| Herman, WH | 2 |
| Holman, RR | 1 |
| Kahn, SE | 1 |
| Alhaider, AA | 1 |
| Korashy, HM | 1 |
| Sayed-Ahmed, MM | 1 |
| Mobark, M | 1 |
| Kfoury, H | 1 |
| Mansour, MA | 1 |
| van Berlo-van de Laar, IR | 1 |
| Vermeij, CG | 1 |
| Doorenbos, CJ | 2 |
| Parke, C | 1 |
| Lien, YH | 1 |
| Cigarrán, S | 1 |
| Rodriguez, ML | 1 |
| Pousa, M | 1 |
| Menéndez, H | 1 |
| Mendez, MJ | 1 |
| Morikawa, A | 1 |
| Ishizeki, K | 1 |
| Iwashima, Y | 1 |
| Yokoyama, H | 1 |
| Muto, E | 1 |
| Oshima, E | 1 |
| Sekiguchi, M | 1 |
| Miura, T | 1 |
| Itoh, H | 1 |
| Ishibashi, Y | 2 |
| Matsui, T | 2 |
| Takeuchi, M | 2 |
| Yamagishi, S | 2 |
| Radwan, MA | 1 |
| Al Taweel, ES | 1 |
| Al-Moghairi, AM | 1 |
| Aloudah, NM | 1 |
| Al Babtain, MA | 1 |
| Al-Amri, HS | 1 |
| Mathiesen, ER | 1 |
| Ringholm, L | 1 |
| Damm, P | 1 |
| Viollet, B | 2 |
| Guigas, B | 1 |
| Sanz Garcia, N | 1 |
| Leclerc, J | 1 |
| Foretz, M | 2 |
| Andreelli, F | 1 |
| Sayed, AA | 1 |
| Khalifa, M | 1 |
| Abd el-Latif, FF | 1 |
| Murff, HJ | 1 |
| Ikizler, TA | 1 |
| Kuritzky, L | 1 |
| del Pozo-Fernández, C | 2 |
| Pardo-Ruiz, C | 2 |
| Sánchez-Botella, C | 2 |
| Blanes-Castañer, V | 1 |
| López-Menchero, R | 2 |
| Gisbert-Sellés, C | 1 |
| Sánchez-Jodar, C | 1 |
| Alvarez-Avellán, L | 1 |
| Martínez-Castelao, A | 1 |
| Górriz, JL | 1 |
| Sola, E | 1 |
| Morillas, C | 1 |
| Jover, A | 1 |
| Coronel, F | 1 |
| Navarro-González, J | 1 |
| De Álvaro, F | 1 |
| Kacso, IM | 1 |
| Bondor, CI | 1 |
| Kacso, G | 1 |
| Kim, J | 1 |
| Shon, E | 1 |
| Kim, CS | 1 |
| Kim, JS | 1 |
| Serra-Tarragón, J | 1 |
| Flynn, C | 1 |
| Heine, RJ | 1 |
| Schure, PJ | 1 |
| de Gooijer, A | 1 |
| van Zanten, AR | 1 |
| Parra, D | 1 |
| Legreid, AM | 1 |
| Beckey, NP | 1 |
| Reyes, S | 1 |
| Kennedy, L | 1 |
| Vigersky, RA | 1 |
| Filmore-Nassar, A | 1 |
| Glass, AR | 1 |
| Wang, W | 1 |
| Guo, XH | 1 |
| Wu, HH | 1 |
| Wang, NH | 1 |
| Xu, XS | 1 |
| Lee, MJ | 1 |
| Feliers, D | 1 |
| Mariappan, MM | 1 |
| Sataranatarajan, K | 1 |
| Mahimainathan, L | 1 |
| Musi, N | 1 |
| Weinberg, JM | 1 |
| Choudhury, GG | 1 |
| Kasinath, BS | 1 |
| Kazory, A | 1 |
| Walsh, K | 1 |
| Harman, E | 1 |
| Talor, Z | 1 |
| Warren, RE | 1 |
| Strachan, MW | 1 |
| Wild, S | 1 |
| McKnight, JA | 1 |
| Shaw, JS | 1 |
| Wilmot, RL | 1 |
| Kilpatrick, ES | 1 |
| Lim, VC | 1 |
| Sum, CF | 1 |
| Chan, ES | 1 |
| Yeoh, LY | 1 |
| Lee, YM | 1 |
| Lim, SC | 1 |
| Runge, S | 1 |
| Mayerle, J | 1 |
| Warnke, C | 1 |
| Robinson, D | 1 |
| Roser, M | 1 |
| Felix, SB | 1 |
| Friesecke, S | 1 |
| Herrington, WG | 1 |
| Levy, JB | 1 |
| Hermann, LS | 1 |
| Magnusson, S | 1 |
| Möller, B | 1 |
| Casey, C | 1 |
| Tucker, GT | 1 |
| Woods, HF | 1 |
| Tikholov, K | 1 |
| Kalpazanova, N | 1 |
| Peshev, P | 1 |
| Kostov, M | 1 |
| Kusinikov, V | 1 |
| Schwarzbeck, A | 1 |
| Hastka, J | 1 |
| Kühnle, F | 1 |
| Rambausek, M | 1 |
| Lacroix, C | 1 |
| De Cagny, B | 1 |
| Fournier, A | 1 |
| Bloomgarden, ZT | 1 |
| Pond, GD | 1 |
| Smyth, SH | 1 |
| Roach, DJ | 1 |
| Hunter, G | 1 |
| Sulkin, TV | 1 |
| Bosman, D | 1 |
| Krentz, AJ | 1 |
| Katayama, S | 1 |
| Nawaz, S | 1 |
| Cleveland, T | 1 |
| Gaines, PA | 1 |
| Chan, P | 1 |
| Imano, E | 1 |
| Kanda, T | 1 |
| Nakatani, Y | 1 |
| Nishida, T | 1 |
| Arai, K | 1 |
| Motomura, M | 1 |
| Kajimoto, Y | 1 |
| Yamasaki, Y | 1 |
| Hori, M | 1 |
| Buysschaert, M | 1 |
| Dramais, AS | 1 |
| Wallemacq, PE | 1 |
| Hermans, MP | 1 |
| Jungmann, E | 1 |
| Helling, T | 1 |
| Jungmann, G | 1 |
| Mertens, C | 1 |
| Snelting, U | 1 |
| Bosma, RJ | 1 |
| Lamberts, PJ | 1 |
| Emslie-Smith, AM | 1 |
| Boyle, DI | 1 |
| Evans, JM | 1 |
| Sullivan, F | 1 |
| Morris, AD | 1 |
| Bian, F | 1 |
| Zhao, P | 1 |
| Gan, SC | 1 |
| Barr, J | 1 |
| Arieff, AI | 1 |
| Pearl, RG | 1 |
| Pyke, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ELMI - Prospective, Randomized, Controlled, Parallel-arm Study to Assess the Effects of the Combined Therapy of Empagliflozin and Linagliptin Compared to Metformin and Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes[NCT02752113] | Phase 3 | 101 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Early Prevention of Diabetes Complications in People With Hyperglycaemia in Europe: e-PREDICE Study[NCT03222765] | 1,000 participants (Anticipated) | Interventional | 2015-03-15 | Recruiting | |||
| Role of Linagliptin in Improving Renal Failure by Improving CD34+ Stem Cell Number, Function and Gene Expression in Renal Function Impaired Type 2 Diabetes Patients.[NCT02467478] | Phase 4 | 31 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial[NCT00081328] | Phase 3 | 699 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus[NCT02526524] | Phase 2 | 571 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4: a Protocol of a Randomized, Parallel, Controlled Trial[NCT03596749] | Phase 3 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed [NCT00279045] | Phase 3 | 4,426 participants (Actual) | Interventional | 2000-01-03 | Completed | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| Metformin Continuation Safety in Diabetic Patients Undergoing Coronary Angiography[NCT04766008] | Phase 4 | 150 participants (Anticipated) | Interventional | 2020-01-15 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured using the Tanita Body Composition Analyzer scale, measured as percentage body fat. (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | percentage of body fat (Mean) |
|---|---|
| Placebo | 30.6 |
| Linagliptin | 31.2 |
Measured via blood biochemistry eGFR, an alternative measurement to spot urine urine microalbumin/creatinine ratio presented above (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | mL/min/1.73m^2 (Mean) |
|---|---|
| Placebo | 84.12 |
| Linagliptin | 79.46 |
Glycemic control is evaluated by measuring HbA1c levels to gauge changes in blood sugar control over last ~90 days (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | percentage of hemoglobin (Mean) |
|---|---|
| Placebo | 7.27 |
| Linagliptin | 6.66 |
Glycemic control is evaluated by measuring fasting blood glucose at time of measurement (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Placebo | 129.68 |
| Linagliptin | 109.93 |
Glycemic control is evaluated by measuring insulin levels at the time of the visit (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | mIU/L (Mean) |
|---|---|
| Placebo | 20.82 |
| Linagliptin | 20.52 |
Vessel health is assessed by looking at Arterial stiffness. Pulse wave velocity (PWV) measures the delay between the pulse registered at the femoral artery from the pulse at the carotid. The difference in distance between these two measurement points from the aortic notch is divided by this delay to give a speed. In stiffer, less healthy vessels, the PWV is increased. We used Vascular Flow and wave measurement equipment, SphygmoCor Central Pressure system from AtCor to perform this calculation. (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | m/s (Mean) |
|---|---|
| Placebo | 10.23 |
| Linagliptin | 10.53 |
(RMR, similar to Resting Energy expenditure measurement): Evaluation of changes in Basal Metabolic Rate (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | Calories/day (Mean) |
|---|---|
| Placebo | 1650.07 |
| Linagliptin | 1657.6 |
Serum endothelial inflammatory markers included here: high sensitivity C-reactive protein (hs-CRP) (NCT02467478)
Timeframe: 12 weeks post Linagliptin or Placebo treatment
| Intervention | mg/L (Mean) |
|---|---|
| Placebo | 3.08 |
| Linagliptin | 5.17 |
Serum endothelial inflammatory markers included here: Interleukin 6 (IL-6) (NCT02467478)
Timeframe: 12 weeks post Linagliptin or Placebo treatment
| Intervention | pg/mL (Mean) |
|---|---|
| Placebo | 2.18 |
| Linagliptin | 5.09 |
We measure using microalbumin/creatinine ratio provided from a random spot urine sample. (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | ratio (Mean) |
|---|---|
| Placebo | 51.12 |
| Linagliptin | 39.70 |
The investigators will use participants' peripheral blood derived CD34+ cells looking at number, function, and gene expression. Post Linagliptin will be compared to pre Linagliptin measurements. Here we report fold changes in protein populations as determined by ELISA. (NCT02467478)
Timeframe: Week 12 expression as a fold difference to Week 0
| Intervention | Fold Change (Mean) | ||||
|---|---|---|---|---|---|
| PECAM | VEGFA | SOD3 | SOD2 | GPX3 | |
| Linagliptin | 2.48 | 2.4 | 1.15 | 2.47 | 1.36 |
| Placebo | 1.48 | 1.43 | 1.13 | 1.40 | 1.59 |
Measured through serum biochemistry Lipid Panel (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | mg/dl (Mean) | |
|---|---|---|
| Cholesterol | Triglycerides | |
| Linagliptin | 159.69 | 124.31 |
| Placebo | 171.45 | 127.76 |
Vessel health is assessed by looking at Arterial stiffness. Augmentation index (AI) is defined as the ratio of the augmentation pressure to the pulse pressure, times 100, to give a percentage. Augmentation index 75 normalizes this value to an estimate of the AI at a heart rate of 75bpm. We used Vascular Flow and wave measurement equipment, SphygmoCor Central Pressure system from AtCor. (NCT02467478)
Timeframe: 12 weeks post beginning Linagliptin or placebo treatment
| Intervention | Percentage (of pulse pressure) (Mean) | |
|---|---|---|
| Augmentation Index 75 | Augmentation Index | |
| Linagliptin | 22.33 | 24.93 |
| Placebo | 21.37 | 24.17 |
Body mass index (BMI) measured in kg per meters squared. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | kg per meters squared (Mean) |
|---|---|
| 1 Metformin Alone | 36.7 |
| 2 Metformin + Rosliglitazone | 38.2 |
| 3 Metformin + Lifestyle Program | 35.3 |
Measured by DXA, both whole body scan and AP-spine scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | g/cm squared (Mean) |
|---|---|
| 1 Metformin Alone | 1.15 |
| 2 Metformin + Rosliglitazone | 1.15 |
| 3 Metformin + Lifestyle Program | 1.15 |
Determined by DXA whole body scan. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. In addition, in about 1/3 of participants DXA scans could not be obtained on participants weighing more than 300 pounds (136 kg), the upper limit in size set by the machine manufacturers. Scans were considered invalid if a body part (e.g., arm, leg) was completely off or partially off the scanner, there was hand-hip overlap, or there was motion or movement during the scan. (NCT00081328)
Timeframe: 24 months
| Intervention | kg (Mean) |
|---|---|
| 1 Metformin Alone | 36.1 |
| 2 Metformin + Rosliglitazone | 39.7 |
| 3 Metformin + Lifestyle Program | 32.2 |
Waist circumference (cm) measured at the iliac crest at its outermost point with the measuring tape placed around the participant in a horizontal plane parallel to the floor at the mark and the measurement teken at the end of normal expiration without the tape compressing the skin. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | cm (Mean) |
|---|---|
| 1 Metformin Alone | 110.8 |
| 2 Metformin + Rosliglitazone | 114.0 |
| 3 Metformin + Lifestyle Program | 108.6 |
A diagnosis was made by an out-of-range value >=95th percentile or systolic >=130 or diastolic >=80 sustained over 6 months or on an anti-hypertensive medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 57 |
| 2 Metformin + Rosliglitazone | 53 |
| 3 Metformin + Lifestyle Program | 45 |
A diagnosis was made from out-of-range value >= 130 mg/dL sustained over 6 months or put on lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 18 |
| 2 Metformin + Rosliglitazone | 16 |
| 3 Metformin + Lifestyle Program | 15 |
A diagnosis was made by an out-of-range value >=150 mg/dL sustained over 6 months or on appropriate lipid lowering medication. (NCT00081328)
Timeframe: Data collected at baseline and during follow-up - 2 years to 6.5 years from randomization.
| Intervention | participants (Number) |
|---|---|
| 1 Metformin Alone | 20 |
| 2 Metformin + Rosliglitazone | 28 |
| 3 Metformin + Lifestyle Program | 22 |
Insulinogenic index determined from OGTT as difference in insulin at 30 minutes minus 0 minutes divided by difference in glucose at 30 minutes minus 0 minutes. The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | uU/mL divided by mg/dL (Median) |
|---|---|
| 1 Metformin Alone | .75 |
| 2 Metformin + Rosliglitazone | .83 |
| 3 Metformin + Lifestyle Program | .71 |
All participants were followed to 24 months. Insulin sensitivity is measured from OGTT as inverse of fasting insulin (mL/uU). The analysis sample includes only participants with 24 month data who had not experienced the primary outcome by that time. (NCT00081328)
Timeframe: 24 months
| Intervention | mL/uU (Median) |
|---|---|
| 1 Metformin Alone | 0.037 |
| 2 Metformin + Rosiglitazone | 0.049 |
| 3 Metformin + Lifestyle Program | 0.039 |
Number of serious adverse events reported during the trial. Participant could have multiple episodes reported. (NCT00081328)
Timeframe: Reported as occurred during study follow-up - 2 years to 6.5 years from randomization.
| Intervention | episodes of serious adverse event (Number) |
|---|---|
| 1 Metformin Alone | 42 |
| 2 Metformin + Rosiglitazone | 34 |
| 3 Metformin + Lifestyle Program | 58 |
Defined as A1c persistently >=8% over a 6-month period or persistent metabolic decompensation (inability to wean insulin within 3 months of initiation or the occurrence of a second episode within three months of discontinuing insulin) (NCT00081328)
Timeframe: Study duration - 2 years to 6.5 years of follow up from randomization
| Intervention | participants (Number) | |
|---|---|---|
| Treatment failure | Did not fail treatment during trial | |
| 1 Metformin Alone | 120 | 112 |
| 2 Metformin + Rosliglitazone | 90 | 143 |
| 3 Metformin + Lifestyle Program | 109 | 125 |
(NCT02526524)
Timeframe: Baseline and 16 weeks after the first dose of study medication
| Intervention | % glycated haemoglobin (Least Squares Mean) |
|---|---|
| 600 mg Met DR qAM | -0.33 |
| 900 mg Met DR qAM | -0.40 |
| 1200 mg Met DR qAM | -0.49 |
| 1500 mg Met DR qAM | -0.62 |
| Placebo | -0.06 |
| 2000 mg Met IR | -1.10 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
29 reviews available for metformin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Lactic Acidosis Associated with Metformin in Patients with Diabetic Kidney Disease.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; La | 2022 |
Dorzagliatin: First Approval.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucokinase; Humans; Hypogl | 2022 |
Dorzagliatin: First Approval.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucokinase; Humans; Hypogl | 2022 |
Dorzagliatin: First Approval.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucokinase; Humans; Hypogl | 2022 |
Dorzagliatin: First Approval.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucokinase; Humans; Hypogl | 2022 |
Pharmacological management of youth with type 2 diabetes and diabetic kidney disease: a comprehensive review of current treatments and future directions.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Metformin; Sod | 2023 |
Insight into the Molecular Mechanism of Diabetic Kidney Disease and the Role of Metformin in Its Pathogenesis.
Topics: Diabetes Mellitus; Diabetic Nephropathies; Endothelial Cells; Humans; Hypoglycemic Agents; Kidney; M | 2023 |
Role of Impaired Nutrient and Oxygen Deprivation Signaling and Deficient Autophagic Flux in Diabetic CKD Development: Implications for Understanding the Effects of Sodium-Glucose Cotransporter 2-Inhibitors.
Topics: Adenylate Kinase; Autophagy; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; | 2020 |
Type 2 diabetes mellitus management in patients with chronic kidney disease: an update.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucagon-Like Peptide-1 Receptor; Humans; Hypogly | 2020 |
Significance of Metformin Use in Diabetic Kidney Disease.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Hypoglycemi | 2020 |
Mechanism and application of metformin in kidney diseases: An update.
Topics: Acidosis, Lactic; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Diabetic Nephro | 2021 |
Update on the Protective Renal Effects of Metformin in Diabetic Nephropathy.
Topics: AMP-Activated Protein Kinases; Animals; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Kidney; | 2017 |
Mitochondria: A Novel Therapeutic Target in Diabetic Nephropathy.
Topics: Animals; Apoptosis; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Metformin; MicroRNAs; Mitoc | 2017 |
Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Topics: Benzamides; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase I | 2018 |
SHIPping out diabetes-Metformin, an old friend among new SHIP2 inhibitors.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Barrier; Humans; Hypoglycem | 2020 |
Bright renoprotective properties of metformin: beyond blood glucose regulatory effects.
Topics: Albuminuria; AMP-Activated Protein Kinases; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2013 |
Novel hypoglycaemic agents: considerations in patients with chronic kidney disease.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors | 2014 |
Metformin and other antidiabetic agents in renal failure patients.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibit | 2015 |
Hypoxia in diabetic kidneys.
Topics: Adenosine Triphosphate; Animals; Diabetes Mellitus; Diabetic Nephropathies; Glomerular Filtration Ra | 2014 |
Metformin-associated lactic acidosis in a peritoneal dialysis patient.
Topics: Acidosis, Lactic; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypo | 2015 |
[Metformin is also recommended in mild and moderate renal failure].
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Ki | 2015 |
Metformin associated lactic acidosis (MALA): clinical profiling and management.
Topics: Acid-Base Equilibrium; Acidosis, Lactic; Aged; Aged, 80 and over; Diabetes Mellitus; Diabetic Nephro | 2016 |
Nephroprotective Effects of Metformin in Diabetic Nephropathy.
Topics: Animals; Diabetic Nephropathies; Endoplasmic Reticulum Stress; Humans; Metformin; Oxidative Stress; | 2017 |
Could metformin be used in patients with diabetes and advanced chronic kidney disease?
Topics: Acidosis, Lactic; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycem | 2017 |
Current management of diabetic patients with kidney disease: a renal‑cardio‑endocrine perspective.
Topics: alpha-Glucosidases; Blood Glucose Self-Monitoring; Blood Pressure; Diabetes Mellitus, Type 2; Diabet | 2017 |
Review: metformin: potential benefits and use in chronic kidney disease.
Topics: Acidosis, Lactic; Blood Glucose; Chronic Disease; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2010 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Saxagliptin plus metformin combination in patients with type 2 diabetes and renal impairment.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV I | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dise | 2013 |
Metformin: effective and safe in renal disease?
Topics: Acidosis, Lactic; Animals; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiop | 2008 |
[Treatment of hypertension associated with diabetes mellitus].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cerebrovascular Disorders; Chroma | 1997 |
Biguanide-associated lactic acidosis. Case report and review of the literature.
Topics: Acidosis, Lactic; Biguanides; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Emigration and Immi | 1992 |
14 trials available for metformin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase | 2021 |
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; | 2020 |
Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data.
Topics: Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathi | 2020 |
Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
Topics: Adult; Aged; Antigens, CD34; Biomarkers; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephro | 2020 |
Circulating adhesion molecules and associations with HbA1c, hypertension, nephropathy, and retinopathy in the Treatment Options for type 2 Diabetes in Adolescent and Youth study.
Topics: Adolescent; Age of Onset; Cell Adhesion Molecules; Child; Combined Modality Therapy; Diabetes Mellit | 2020 |
Improved glycemic control with minimal systemic metformin exposure: Effects of Metformin Delayed-Release (Metformin DR) targeting the lower bowel over 16 weeks in a randomized trial in subjects with type 2 diabetes.
Topics: Blood Glucose; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Doubl | 2018 |
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease.
Topics: Aged; Cardiovascular Diseases; Cause of Death; Darbepoetin alfa; Diabetes Mellitus, Type 2; Diabetic | 2019 |
Effects of sevelamer carbonate on advanced glycation end products and antioxidant/pro-oxidant status in patients with diabetic kidney disease.
Topics: Adiponectin; Age Factors; Aged; Albuminuria; Chelating Agents; Diabetes Mellitus, Type 2; Diabetic N | 2015 |
Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
Topics: Aged; Blood Glucose; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-P | 2015 |
Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy.
Topics: Adult; Aged; Albuminuria; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diab | 2011 |
Pioglitazone reduces urinary albumin excretion in renin-angiotensin system inhibitor-treated type 2 diabetic patients with hypertension and microalbuminuria: the APRIME study.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti | 2011 |
Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry.
Topics: Acidosis, Lactic; Cardiac Catheterization; Chromatography, High Pressure Liquid; Contrast Media; Cre | 2011 |
Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Cholesterol; Cholesterol, HDL; Chromans | 1998 |
[Clinical study on treatment of incipient diabetic nephropathy by integrated traditional Chinese and Western medicine].
Topics: Adult; Aged; Capsules; Diabetic Nephropathies; Drug Therapy, Combination; Drugs, Chinese Herbal; Fem | 2000 |
136 other studies available for metformin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Structure-activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy.
Topics: Alkaloids; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Female; Hep G2 Cells; H | 2020 |
Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy.
Topics: Aldehyde Reductase; Animals; Antioxidants; Benzoxazoles; Diabetes Mellitus, Experimental; Diabetic N | 2021 |
Berberine Improves the Protective Effects of Metformin on Diabetic Nephropathy in db/db Mice through Trib1-dependent Inhibiting Inflammation.
Topics: Animals; Berberine; Diabetic Nephropathies; Disease Models, Animal; Disease Progression; Drug Synerg | 2021 |
Identification of circular RNAs and functional competing endogenous RNA networks in human proximal tubular epithelial cells treated with sodium-glucose cotransporter 2 inhibitor dapagliflozin in diabetic kidney disease.
Topics: Benzhydryl Compounds; Diabetes Mellitus; Diabetic Nephropathies; Epithelial Cells; Glucose; Glucosid | 2022 |
Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
Topics: Adenine; Animals; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; | 2022 |
Effects of Metformin on Renal Function, Cardiac Function, and Inflammatory Response in Diabetic Nephropathy and Its Protective Mechanism.
Topics: C-Reactive Protein; Diabetes Mellitus; Diabetic Nephropathies; Humans; Interleukin-6; Kidney; Liragl | 2022 |
Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Cross- | 2022 |
Quality of care and prescription patterns among patients with diabetic kidney disease-a large-scale cohort study from Taiwanese clinics.
Topics: Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycated Hemogl | 2022 |
Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy.
Topics: Activins; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycoproteins; Kidney; M | 2023 |
Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy.
Topics: Activins; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycoproteins; Kidney; M | 2023 |
Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy.
Topics: Activins; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycoproteins; Kidney; M | 2023 |
Metformin suppresses LRG1 and TGFβ1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy.
Topics: Activins; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glycoproteins; Kidney; M | 2023 |
Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hyperglycemia; Kidn | 2023 |
Gallic acid improves the metformin effects on diabetic kidney disease in mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gallic | 2023 |
Dapagliflozin and metformin in combination ameliorates diabetic nephropathy by suppressing oxidative stress, inflammation, and apoptosis and activating autophagy in diabetic rats.
Topics: Animals; Apoptosis; Autophagy; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic | 2024 |
Reports of Lactic Acidosis Attributed to Metformin, 2015-2018.
Topics: Acidosis, Lactic; Adult; Adverse Drug Reaction Reporting Systems; Aged; Diabetic Nephropathies; Fema | 2020 |
Metformin alleviates oxidative stress and enhances autophagy in diabetic kidney disease via AMPK/SIRT1-FoxO1 pathway.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Cells, Cultured; Diabetes Mellitus, Experimental; | 2020 |
Metformin is associated with increase in lactate level in elderly patients with type 2 diabetes and CKD stage 3: A case-control study.
Topics: Age Factors; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Neph | 2020 |
Metformin reduces TRPC6 expression through AMPK activation and modulates cytoskeleton dynamics in podocytes under diabetic conditions.
Topics: AMP-Activated Protein Kinases; Animals; Cytoskeleton; Diabetes Mellitus, Type 2; Diabetic Nephropath | 2020 |
Metformin rescues Parkin protein expression and mitophagy in high glucose-challenged human renal epithelial cells by inhibiting NF-κB via PP2A activation.
Topics: Blotting, Western; Diabetic Nephropathies; Enzyme Activation; Epithelial Cells; Glucose; Humans; Hyp | 2020 |
Metformin Reduces the Senescence of Renal Tubular Epithelial Cells in Diabetic Nephropathy via the MBNL1/miR-130a-3p/STAT3 Pathway.
Topics: Animals; Cells, Cultured; Cellular Senescence; Diabetes Mellitus, Experimental; Diabetic Nephropathi | 2020 |
The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Cause of Death; Cohort Studies; Diabetes Mellitus, Type 2 | 2020 |
Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Topics: Acidosis, Lactic; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; G | 2020 |
Metformin inhibits extracellular matrix accumulation, inflammation and proliferation of mesangial cells in diabetic nephropathy by regulating H19/miR-143-3p/TGF-β1 axis.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cell Proliferation; Diabetic Nephropathies; Extracellu | 2020 |
Positive interaction of mangiferin with selected oral hypoglycemic drugs: a therapeutic strategy to alleviate diabetic nephropathy in experimental rats.
Topics: Animals; Antioxidants; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetic Nephropathies; D | 2020 |
2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.
Topics: Cardiology; Cardiovascular Diseases; Consensus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Di | 2020 |
Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948-955.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Metformin | 2020 |
Response to Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948-955.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Metformin | 2020 |
Characterization and anti-diabetic nephropathic ability of mycelium polysaccharides from Coprinus comatus.
Topics: Animals; Antioxidants; Coprinus; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycem | 2021 |
Huangkui capsule in combination with metformin ameliorates diabetic nephropathy via the Klotho/TGF-β1/p38MAPK signaling pathway.
Topics: Animals; Cell Line; Cell Proliferation; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Die | 2021 |
Effects of HuoxueJiangtang decoction alone or in combination with metformin on renal function and renal cortical mRNA expression in diabetic nephropathy rats.
Topics: Animals; Blood Glucose; Captopril; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug The | 2020 |
Autophagy blockade mechanistically links proton pump inhibitors to worsened diabetic nephropathy and aborts the renoprotection of metformin/enalapril.
Topics: Albuminuria; Animals; Autophagy; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diet, High | 2021 |
Metformin ameliorates the severity of experimental Alport syndrome.
Topics: Animals; Collagen Type IV; Diabetic Nephropathies; Disease Models, Animal; Hypoglycemic Agents; Kidn | 2021 |
Preventing the onset of diabetes-induced chronic kidney disease during prediabetes: The effects of oleanolic acid on selected markers of chronic kidney disease in a diet-induced prediabetic rat model.
Topics: Animals; Biomarkers; Diabetic Nephropathies; Diet; Diet, High-Fat; Dietary Carbohydrates; Glomerular | 2021 |
Metformin mediates MicroRNA-21 regulated circulating matrix metalloproteinase-9 in diabetic nephropathy: an in-silico and clinical study.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Matrix Metalloproteinase 9; Metformin; Mi | 2023 |
Diabetic kidney disease in patients with type 2 diabetes mellitus: a cross-sectional study.
Topics: Age Factors; Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Cross-Sectional Studies; Diabete | 2021 |
Malaysian Propolis and Metformin Synergistically Mitigate Kidney Oxidative Stress and Inflammation in Streptozotocin-Induced Diabetic Rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Creatinine; Diabetes Mellitus, Experimental; Diabet | 2021 |
Clinical Characteristics and Risk of Diabetic Complications in Data-Driven Clusters Among Type 2 Diabetes.
Topics: Adult; Aged; Blood Pressure; China; Cluster Analysis; Cross-Sectional Studies; Diabetes Mellitus, Ty | 2021 |
L-ergothioneine and its combination with metformin attenuates renal dysfunction in type-2 diabetic rat model by activating Nrf2 antioxidant pathway.
Topics: Animals; Antioxidants; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropa | 2021 |
Metformin attenuates renal tubulointerstitial fibrosis via upgrading autophagy in the early stage of diabetic nephropathy.
Topics: Animals; Autophagy; Biomarkers; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial | 2021 |
Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: A GoDarts study.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Aged, 80 and over; Case-Control Studies; Diabetes Melli | 2017 |
Renal function markers and metformin eligibility.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; | 2018 |
Effect of human umbilical cord blood-derived mononuclear cells on diabetic nephropathy in rats.
Topics: Animals; Blood Glucose; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Fetal B | 2018 |
Metformin-induced encephalopathy: the role of thiamine.
Topics: Adult; Brain Diseases; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Metformin; Thiam | 2018 |
Range of therapeutic metformin concentrations in clinical blood samples and comparison to a forensic case with death due to lactic acidosis.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Chromatography, Liquid; Diabetes Mellitus, Type 2; | 2018 |
MIF/CD74 axis is a target for metformin therapy in diabetic podocytopathy - real world evidence.
Topics: Adult; Antigens, Differentiation, B-Lymphocyte; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic N | 2018 |
Metformin attenuates renal medullary hypoxia in diabetic nephropathy through inhibition uncoupling protein-2.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Hypoxia; Kidn | 2019 |
Ameliorative effects of protodioscin on experimental diabetic nephropathy.
Topics: Albuminuria; Animals; Blood Glucose; Blood Urea Nitrogen; Carboxymethylcellulose Sodium; Cholesterol | 2018 |
Dethroning the king?: The future of metformin as first line therapy in type 2 diabetes.
Topics: Contraindications, Drug; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Administration Sche | 2019 |
Hyperglycemia induces NF-κB activation and MCP-1 expression via downregulating GLP-1R expression in rat mesangial cells: inhibition by metformin.
Topics: Animals; Cell Line; Chemokine CCL2; Diabetic Nephropathies; Exenatide; Glucagon-Like Peptide-1 Recep | 2019 |
Basic Research in Diabetic Nephropathy Health Care: A study of the Renoprotective Mechanism of Metformin.
Topics: Animals; Biomedical Research; Diabetic Nephropathies; Hypoglycemic Agents; Klotho Proteins; Membrane | 2019 |
Evaluation of Kidney Function Parameters in Diabetic Rats Following Virgin Coconut Oil Diet.
Topics: Animals; Blood Urea Nitrogen; Body Weight; Coconut Oil; Creatinine; Diabetes Mellitus, Experimental; | 2019 |
Maintenance of endothelial guanosine triphosphate cyclohydrolase I ameliorates diabetic nephropathy.
Topics: Albuminuria; Animals; Biopterins; Cell Line; Diabetes Mellitus, Experimental; Diabetic Nephropathies | 2013 |
[Diabetes treatment in patients with chronic kidney disease].
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Substitution; Drug Therapy, Combinatio | 2013 |
[How I treat ... with metformin a diabetic patient with moderate renal insufficiency].
Topics: Contraindications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; M | 2013 |
Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
Topics: Age Factors; Aged; Albuminuria; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; | 2013 |
Medical care of type 2 diabetes mellitus in light of international and national recommendations: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Retinopathy; Fe | 2013 |
Renoprotective effect of metformin.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypoglycemic Agents; Metformin | 2013 |
AMPK-mediated downregulation of connexin43 and premature senescence of mesangial cells under high-glucose conditions.
Topics: AMP-Activated Protein Kinases; Cells, Cultured; Cellular Senescence; Connexin 43; Cyclin-Dependent K | 2014 |
Prescription-medication sharing among family members: an unrecognized cause of a serious drug adverse event in a patient with impaired renal function.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug-Related Side Effects | 2015 |
Involvement of the AMPK-PTEN pathway in insulin resistance induced by high glucose in cultured rat podocytes.
Topics: AMP-Activated Protein Kinases; Animals; Diabetic Nephropathies; Female; Glucose; Insulin Resistance; | 2014 |
Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study.
Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, | 2014 |
How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
Topics: Aged; Aged, 80 and over; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Ne | 2014 |
My patient's diabetic kidney disease has progressed to stage 4; should I discontinue metformin?
Topics: Acidosis, Lactic; Canada; Diabetic Nephropathies; Disease Progression; Dose-Response Relationship, D | 2014 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitu | 2015 |
Evaluation of hypoglycemic efficacy of tangningtongluo formula, a traditional Chinese Miao medicine, in two rodent animal models.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Diabeti | 2014 |
[Therapy of chronic renal failure. Family practitioner and nephrologist hand in hand].
Topics: Contraindications; Contrast Media; Cooperative Behavior; Diabetic Nephropathies; Family Practice; Hu | 2015 |
Metformin alleviates high glucose-mediated oxidative stress in rat glomerular mesangial cells by modulation of p38 mitogen-activated protein kinase expression in vitro.
Topics: Animals; Diabetic Nephropathies; Gene Expression Regulation; Glucose; Mesangial Cells; Metformin; Ox | 2015 |
Estimating kidney function and use of oral antidiabetic drugs in elderly.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Biomarkers; Creatinine; Cross-Sectional | 2015 |
Taurine can enhance the protective actions of metformin against diabetes-induced alterations adversely affecting renal function.
Topics: Animals; Blood Glucose; Cytoprotection; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dru | 2015 |
[Effective prevention of coronary heart disease by early diabetes therapy].
Topics: Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early M | 2015 |
Metformin ameliorates lipotoxicity-induced mesangial cell apoptosis partly via upregulation of glucagon like peptide-1 receptor (GLP-1R).
Topics: Animals; Apoptosis; Cell Line; Diabetic Nephropathies; Glucagon-Like Peptide-1 Receptor; Mesangial C | 2015 |
Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine.
Topics: Adult; Aged; Aged, 80 and over; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug | 2015 |
Unexpectedly long half-life of metformin elimination in cases of metformin accumulation.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Algorithms; Blood; Diabetes Mellitus, Type 2; Diabetic | 2016 |
Metformin initiation and renal impairment: a cohort study in Denmark and the UK.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Denmark; Diabetes Mellitus, Type 2; Diabetic Nephrop | 2015 |
Diabetes: Metformin and renal insufficiency-is 45, or even 30, the new 60?
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Prescriptions; Female; Glomerula | 2015 |
[Metformin is commonly used in patients with renal impairment].
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Male; Metfor | 2015 |
Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cell Line; Cell Survival; Cytoprotection; Diabetic Nephrop | 2016 |
Prescribing of metformin based on estimated GFR rather than serum creatinine expands the eligible population and is likely safe.
Topics: Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Prescriptions; Female; Glomerula | 2016 |
Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study.
Topics: Acid-Base Equilibrium; Acidosis, Lactic; Acute Kidney Injury; Adult; Aged; Cross-Sectional Studies; | 2016 |
[New aspects in prevention and therapy of diabetic nephropathy].
Topics: Acidosis, Lactic; Diabetic Nephropathies; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; | 2016 |
Lycium barbarum Polysaccharide Mediated the Antidiabetic and Antinephritic Effects in Diet-Streptozotocin-Induced Diabetic Sprague Dawley Rats via Regulation of NF-κB.
Topics: Animals; Anti-Inflammatory Agents; Blood Glucose; Cytokines; Diabetes Mellitus, Experimental; Diabet | 2016 |
Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Neph | 2016 |
Effects of the Nrf2 Protein Modulator Salvianolic Acid A Alone or Combined with Metformin on Diabetes-associated Macrovascular and Renal Injury.
Topics: Alkenes; Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Gl | 2016 |
Peritoneal dialysis treatment of metformin-associated lactic acidosis in a diabetic nephropathy patient
.
Topics: Acidosis, Lactic; Aged; Diabetic Nephropathies; Dialysis Solutions; Humans; Hypoglycemic Agents; Kid | 2016 |
Geniposide reduces development of streptozotocin-induced diabetic nephropathy via regulating nuclear factor-kappa B signaling pathways.
Topics: Animals; Blotting, Western; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Response R | 2017 |
Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; Me | 2017 |
Effect of Cichorium intybus L. seed extract on renal parameters in experimentally induced early and late diabetes type 2 in rats.
Topics: Animals; Blood Glucose; Cichorium intybus; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nep | 2017 |
The Correlation Between Urinary 8-Iso-Prostaglandin F2α and Hydrogen Peroxide Toward Renal Function in T2DM Patients Consuming Sulfonylurea and Combination of Metformin-Sulfonylurea.
Topics: Aged; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dinopr | 2018 |
mTORC1 inhibitors rapamycin and metformin affect cardiovascular markers differentially in ZDF rats.
Topics: Animals; Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dis | 2017 |
Changes in albumin excretion in the diabetes prevention program.
Topics: Adult; Aged; Albuminuria; Creatinine; Diabetes Mellitus; Diabetic Nephropathies; Female; Humans; Hyp | 2009 |
Metformin-induced encephalopathy without lactic acidosis in a patient with contraindication for metformin.
Topics: Acidosis, Lactic; Brain Diseases; Contraindications; Diabetes Mellitus, Type 1; Diabetic Nephropathi | 2009 |
Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidy | 2010 |
Limitations of metformin use in patients with kidney disease: are they warranted?
Topics: Acidosis, Lactic; Adolescent; Adult; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2010 |
Insulin and metformin may prevent renal injury in young type 2 diabetic Goto-Kakizaki rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2011 |
Tubular injury in a rat model of type 2 diabetes is prevented by metformin: a possible role of HIF-1α expression and oxygen metabolism.
Topics: Adenylate Kinase; Analysis of Variance; Animals; Cell Line; Cysteine Proteinase Inhibitors; Diabetes | 2011 |
Metformin attenuates streptozotocin-induced diabetic nephropathy in rats through modulation of oxidative stress genes expression.
Topics: Animals; Blood Glucose; Catalase; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Dose-Resp | 2011 |
Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early | 2011 |
Quiz page June 2011. Profound metabolic acidosis and abdominal pain in a diabetic patient on long-term hemodialysis.
Topics: Abdominal Pain; Acidosis, Lactic; Diabetic Nephropathies; Diagnosis, Differential; Follow-Up Studies | 2011 |
Transient vision loss in a patient with severe metformin-associated lactic acidosis.
Topics: Acidosis, Lactic; Acute Disease; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Humans; Hypoglyc | 2012 |
Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Biphenyl Compounds; Cattle; Cells, Cult | 2012 |
Pregnancy management of women with pregestational diabetes.
Topics: Congenital Abnormalities; Counseling; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Me | 2011 |
Fenugreek attenuation of diabetic nephropathy in alloxan-diabetic rats: attenuation of diabetic nephropathy in rats.
Topics: Alloxan; Animals; Anti-Inflammatory Agents; Antioxidants; Catalase; Diabetes Mellitus, Experimental; | 2012 |
Comparative effectiveness of incident oral antidiabetic drugs on kidney function.
Topics: Administration, Oral; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Femal | 2012 |
The role of combination therapy in type 2 diabetes in the post-ACCORD era.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; D | 2012 |
Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients.
Topics: Acidosis, Lactic; Aged; Carbamates; Consensus Development Conferences as Topic; Contraindications; D | 2012 |
About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes.
Topics: Consensus Development Conferences as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disea | 2012 |
Soluble serum Klotho in diabetic nephropathy: relationship to VEGF-A.
Topics: Aged; Albuminuria; Biomarkers; Case-Control Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic | 2012 |
Metformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression.
Topics: AMP-Activated Protein Kinases; Apoptosis; Cells, Cultured; Chemokine CCL2; Diabetic Nephropathies; D | 2012 |
Renal podocyte injury in a rat model of type 2 diabetes is prevented by metformin.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Albuminuria; Animals; Antioxidants; Apoptosis; Deoxyguanosine; Diabetes | 2012 |
Antidiabetics in chronic kidney disease: new questions to new and classical drugs.
Topics: Consensus Development Conferences as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disea | 2012 |
Discrepancies between the summary of characteristics and the recommended use of metformin in the treatment of type 2 diabetes mellitus patients.
Topics: Consensus Development Conferences as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disea | 2012 |
[Does a reduced kidney function (creatinine clearance 10-15 ml/min), without acidosis, increase the risk for the rise of lactic acidosis caused by metformin?].
Topics: Acidosis, Lactic; Contraindications; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diabetic Neph | 2002 |
Unexpected survival from severe metformin-associated lactic acidosis.
Topics: Acidosis, Lactic; Aged; Contraindications; Diabetic Nephropathies; Female; Heart Arrest; Humans; Hyp | 2003 |
Metformin monitoring and change in serum creatinine levels in patients undergoing radiologic procedures involving administration of intravenous contrast media.
Topics: Aged; Contraindications; Contrast Media; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathi | 2004 |
[Nothing here follows protocol F. Elderly diabetic patients are not "DMP qualified"].
Topics: Aged; Blood Glucose; Comorbidity; Contraindications; Diabetes Mellitus, Type 2; Diabetic Foot; Diabe | 2005 |
Renal status among patients using metformin in a primary care setting.
Topics: Adolescent; Adult; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycem | 2005 |
Thyrotropin suppression by metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Interactions; Female; Goiter; Graves D | 2006 |
[Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fenofibrate; Kidney; Lipid Metabolism; M | 2006 |
A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Carrier Proteins; Cells, Culture | 2007 |
Is metformin safe in patients with mild renal insufficiency?
Topics: Diabetic Nephropathies; Humans; Hypoglycemic Agents; Hypotension; Lung Diseases; Male; Metformin; Mi | 2007 |
Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin.
Topics: Blood Glucose; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Fil | 2007 |
Establishing pragmatic estimated GFR thresholds to guide metformin prescribing.
Topics: Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Prescriptions; Female; Glomerular Filt | 2007 |
[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Th | 2007 |
Lactate levels in Asian patients with type 2 diabetes mellitus on metformin and its association with dose of metformin and renal function.
Topics: Acidosis, Lactic; Asia; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; | 2007 |
Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation?
Topics: Acidosis, Lactic; Aged; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Male; Metformin | 2008 |
Lactic acidosis during metformin treatment in an elderly diabetic patient with impaired renal function.
Topics: Acidosis; Aged; Diabetes Mellitus; Diabetic Nephropathies; Digitoxin; Female; Humans; Kidney Failure | 1981 |
[Treatment of diabetics with metformin].
Topics: Adult; Aged; Chronic Disease; Diabetes Mellitus; Diabetic Nephropathies; Diabetic Retinopathy; Drug | 1980 |
Metformin-associated lactic acidosis in diabetic patients with acute renal failure.
Topics: Acidosis, Lactic; Acute Kidney Injury; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; G | 1995 |
Metformin-associated lactic acidosis in diabetic patients with acute renal failure. A critical analysis of its pathogenesis and prognosis.
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Eryt | 1994 |
Conference report: renal disease, metformin, and the adipocyte.
Topics: Adipocytes; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabet | 1996 |
Metformin and contrast media: genuine risk or witch hunt?
Topics: Contraindications; Contrast Media; Diabetes Mellitus; Diabetic Ketoacidosis; Diabetic Nephropathies; | 1996 |
Contraindications to metformin therapy in patients with NIDDM.
Topics: Acidosis, Lactic; Alcoholism; Contraindications; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; D | 1997 |
Clinical risk associated with contrast angiography in metformin treated patients: a clinical review.
Topics: Acidosis, Lactic; Adult; Aged; Aged, 80 and over; Angiography; Contraindications; Contrast Media; Cr | 1998 |
Hyperhomocysteinemia in type 2 diabetes: relationship to macroangiopathy, nephropathy, and insulin resistance.
Topics: Aged; Cohort Studies; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephrop | 2000 |
[Intensified conventional insulin therapy in patients with type 2 diabetes mellitus. Positive long-term effects of insulin lispro on metabolic control and microalbuminuria].
Topics: Aged; Albuminuria; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Dr | 2001 |
Use of urea containing dialysate to avoid disequilibrium syndrome, enabling intensive dialysis treatment of a diabetic patient with renal failure and severe metformin induced lactic acidosis.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypoglyce | 2001 |
Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines.
Topics: Cohort Studies; Contraindications; Databases as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2001 |
General treatment of diabetes.
Topics: Acidosis; Diabetes Mellitus; Diabetic Coma; Diabetic Nephropathies; Diabetic Retinopathy; Diet, Diab | 1970 |